BioCardia Announces FDA Approval for Groundbreaking Heart Failure Treatment

BioCardia Logo

BioCardia, Inc., a prominent player in the development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, has recently announced a significant milestone. The U.S. Food and Drug Administration (FDA) has approved the Phase III clinical trial protocol for BioCardia’s CardiAMP autologous cell therapy. This therapy is designed for patients suffering from ischemic heart […]

Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting

BioCardia Logo

SUNNYVALE, Calif., March 06, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces that detailed echocardiography data from the roll-in cohort of the Phase III CardiAMP® Cell Therapy Heart Failure Trial is being presented today at the American College of Cardiology annual meeting by […]